MolNFT v1 · #135817 · protein
Met tyrosine kinase inhibition enhances the antitumor efficacy of an hgf antibody
5UAD · Hepatocyte growth factor receptor: “Met tyrosine kinase inhibition enhances the antitumor efficacy of an hgf antibody”. X-ray diffraction, 2 ligands (84P, CL), 2 pockets (best druggability 0.64). MolNFT v1 #135817 on GenesisL1: 3D…
- PDB
- 5UAD
- Type
- protein
- Length
- 291 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Hepatocyte growth factor receptor
- EC
- 2.7.10.1
- UniProt
- P08581
- Ligands
- 84P, CL
- Pockets
- 2 · best druggability 0.64
Structure
x-ray diffraction · 1 distinct chain · 39% helix, 15% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Hepatocyte growth factor receptor (EC 2.7.10.1) | protein | 291 | 39% helix, 15% strand | P08581 |
Ligands and binding sites
- 84P · N-(6-{[6-(1-methyl-1H-pyrazol-4-yl)-1H-benzotriazol-1-yl]methyl}imidazo[1,2-b]pyridazin-2-yl) cyclopropanecarboxamide · ligand · chains A
- CL · Chloride ion · ion · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 198 | 0.64 | 0.83 | 26 | 84P |
| 2 | 221 | 0.47 | 0.73 | 28 | empty |
Compared structures
- 5UAD · MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P08581
- Elsewhere: RCSB PDB 5UAD · PDBe 5UAD · UniProt P08581
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.